Nature Reviews Drug Discovery
Volume 7, No 5 May 2008
Main pages for finding content:
2006 ISI Impact Factor 20.970(*Source of Impact Factor data)
Current Issue
News
Cardiovascular imaging in the light of ENHANCE
Bethan Hughes
Following the high-profile ENHANCE trial, in which addition of the cardiovascular drug ezetimibe to statin therapy did not result in additional improvement in an imaging-based measure of atherosclerosis, what are the implications for such studies in the future?
Advance online publication
Perspective
Follow–on biologics: data exclusivity and the balance between innovation and competition
Henry Grabowski
Legislation to create a regulatory pathway for follow–on biologics is currently being considered by the US Congress. This article discusses the critical issue of the period of data exclusivity for innovator companies, which has a major influence on the potential to recoup their R&D investment.
Current issue
Review
Aliskiren: the first renin inhibitor for clinical treatment
Chris Jensen, Peter Herold & Hans Rudolf Brunner
Renin — a protease with a key role in blood pressure regulation — has long been an attractive target, but has also proved to be challenging. This article describes how these challenges were tackled in the discovery and development of the first approved renin inhibitor, aliskiren.
Current issue
Research Highlights
-
Antiparasitics:
Fighting back against resistant worms
-
Autoimmune diseases:
Targeting sugar coating
-
High-throughput screening:
First fruits
Current issue
Review
The TWEAK–Fn14 cytokine–receptor axis: discovery, biology and therapeutic targeting
Jeffrey A. Winkles
TWEAK, a member of the tumour necrosis superfamily, is a multifunctional cytokine that binds to the cell–surface receptor Fn14. This article highlights the potential of the TWEAK–Fn14 axis as a target for the treatment of cancer, autoimmune diseases and stroke.
Current issue
Careers and recruitment
Vaccine research
Ian Frazer & Baoming Jiang
Vaccine R&D has been revitalized recently in part owing to major commercial successes and increased incentives for products that address neglected diseases.
Noticeboard
SciBX: Science - Business eXchange from NPG and BioCentury
Science-Business eXchange is a groundbreaking weekly publication that will transform your ability to efficiently identify and evaluate new developments in science and technology that have commercial and investment potential within the biotechnology and pharmaceutical arena. Sign up for a FREE TRIAL and see how SciBX can save you time and effort by selecting and distilling the most important science each week.
Focus on Antivirals
This joint Web Focus from Nature Reviews Drug Discovery and Nature Biotechnology hosts a collection of reviews, research highlights and commentaries covering the science and business of antiviral drug R&D. Thanks to the generous support of Pfizer (principal sponsor) and Gilead (supporting sponsor), content in the focus is freely available until June 2008.
NPG BioPartnering site
This site is dedicated to small and large companies looking for commercial partnerships and finding out more about licensing.
Nature Reports Stem Cells
Nature Reports Stem Cells for the latest news, research, comment and analysis about stem cells and their implications.
Career snapshots
Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field.
Naturejobs spotlights and regions
Interactive regional map linking to information, features and career opportunities worldwide.
Natureevents
A comprehensive resource of information on scientific events and conferences around the world.
Journal Citation Reports, Thomson, 2006